Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05202587 · ClinicalTrials.gov registry record
The Evaluation of the Agreement Between the NVHO in the Automatic Fluid Quantification and Cirrus OCT
A clinical trial, sponsored by Notal Vision.
- Completed
- Registry status
- 386
- Enrollment target
NCT05202587: Completed study, sponsored by Notal Vision.
NCT05202587 is a clinical trial that has completed, run by Notal Vision. The registered enrollment target is 386 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05202587 has completed, sponsored by Notal Vision.
- COMPLETED
- Registry status
- 386 participants
- Enrollment target
Study Summary
This multi-center study will enroll Adult subjects diagnosed with neo-vascular age-related macular degeneration (NV-AMD) in at least one eye at the time of enrollment. the subject study duration for this study is one day (2-3 hours). Each study site will have two NVHO devices and one Cirrus 5000 and the patients will be scand on the two NVHO devices and one Cirrus device as a part of the study flow. At the Study Visit, fluid must be present in approximately 280 study eyes and fluid must be absent from 20 study eyes. Each subject will only have one study eye. The fluid status will be determined by the investigator while reviewing an acceptable screening Cirrus OCT volume scan.
Primary Outcome
volume \[nl\] of the Intra-retinal fluid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 386 participants |
| Start Date | 2021-11-10 |
| Est. Completion | 2023-01-12 |
What the finished NCT05202587 record still lists
NCT05202587 is an observational study that tracks outcomes without assigning an intervention. The registered 386 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT05202587 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05202587 about?
NCT05202587 is a clinical study titled "The Evaluation of the Agreement Between the NVHO in the Automatic Fluid Quantification and Cirrus OCT". This multi-center study will enroll Adult subjects diagnosed with neo-vascular age-related macular degeneration (NV-AMD) in at least one eye at the time of enrollment. the subject study duration for this study is one day (2-3 hours). Each study site will have two NVHO devices and one Cirrus 5000 and...
What is the current status of trial NCT05202587?
This trial is currently completed. The enrollment target is 386 participants. The study started on 2021-11-10. Estimated completion is 2023-01-12.
Who is sponsoring clinical trial NCT05202587?
This trial is sponsored by Notal Vision, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05645107 · 386 participants · Phase 3
A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma
- NCT05896189 · 386 participants · NA
Cognitive Training for Cancer Related Cognitive Impairment in Breast Cancer Survivors
- NCT06686121 · 386 participants · Phase 3
Improving Mobility After Revascularization in Peripheral Artery Disease
- NCT07424547 · 386 participants · Phase 1
Phase I Study of SYS6043 in Patients With Advanced/Metastatic Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI